Evidence map›Paper›PMID 36417130›Full record

ArticleCellular oncology (Dordrecht, Netherlands)2023

Single cell profiling of γδ hepatosplenic T-cell lymphoma unravels tumor cell heterogeneity associated with disease progression.

Wei Song, Haixi Zhang, Fan Yang, Kiichi Nakahira, Cheng Wang, Keqian Shi, Ruoyu Zhang

Open access · hybridAbstract read
In one paragraph

Article in Cellular oncology (Dordrecht, Netherlands), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.7field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. γδ T cells: origin and fate, subsets, diseases and immunotherapy.Signal transduction and targeted therapy · 2023
    Review
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 2 countries.

Wei Song *Faculty of Life Science and Technology, Kunming University of Science and Technology, Kunming, 650500, Yunnan, People's Republic of China.
Haixi Zhang *Department of Hematology, The First People's Hospital of Yunnan Province, Kunming, 650032, Yunnan, People's Republic of China.
Fan YangSchool of Medicine, Kunming University of Science and Technology, Kunming, 650500, Yunnan, People's Republic of China.
Kiichi NakahiraDepartment of Pharmacology, Nara Medical University, Kashihara, Nara, 634-8521, Japan.
Cheng WangInnovec Biotherapeutics, Inc., Beijing, 100193, People's Republic of China.
Keqian ShiDepartment of Hematology, The First People's Hospital of Yunnan Province, Kunming, 650032, Yunnan, People's Republic of China. shikeqian1@outlook.com.
Ruoyu ZhangInnovec Biotherapeutics, Inc., Beijing, 100193, People's Republic of China. zry0510@gmail.com.
First People's Hospital of Yunnan Province · CNKunming University of Science and Technology · CNNara Medical University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeHepatosplenic T-cell lymphoma (HSTCL), mostly derived from γδ T cells, is a rare but very aggressive lymphoma with poor outcomes. In this study, we generated the first single cell landscape for this rare disease and characterized the molecular pathogenesis underlying the disease progression.

methodsWe performed paired single cell RNA-seq and T cell receptor (TCR) sequencing on biopsies from a HSTCL patient pre- and post- chemotherapy treatments. Following by a series of bioinformatics analysis, we investigated the gene expression profile of γδ HSTCS as well as its tumor microenvironment (TME).

resultsWe characterized the unique gene expressing signatures of malignant γδ T cells with a set of marker genes were newly identified in HSTCL (AREG, PLEKHA5, VCAM1 etc.). Although the malignant γδ T cells were expanded from a single TCR clonotype, they evolved into two transcriptionally distinct tumor subtypes during the disease progression. The Tumor_1 subtype was dominant in pre-treatment samples with highly aggressive phenotypes. While the Tumor_2 had relative mild cancer hallmark signatures but expressed genes associated with tumor survival signal and drug resistance (IL32, TOX2, AIF1, AKAP12, CD38 etc.), and eventually became the main tumor subtype post-treatment. We further dissected the tumor microenvironment and discovered the dynamically rewiring cell-cell interaction networks during the treatment. The tumor cells had reduced communications with the microenvironment post-treatment.

conclusionsOur study reveals heterogenous and dynamic tumor and microenvironment underlying pathogenesis of HSTCL and may contribute to identify novel targets for diagnosis and treatment of HSTCL in the future.

Indexed as

Liver NeoplasmsLymphoma, T-CellSplenic NeoplasmsDisease ProgressionHumansReceptors, Antigen, T-Cell, gamma-deltaTumor MicroenvironmentReceptors, Antigen, T-Cell, gamma-deltaHepatosplenic T-cell lymphomaSingle cell RNA-seqSingle cell TCR-seqγδ T cells

Identifiers

PMID36417130
PMCPMC9947078
OpenAlexW4309716492

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.